Tirzepatide
Research profile · How we handle evidence
The "next-gen Ozempic" that works even better. It targets two hormones instead of one, leading to up to 25% body weight loss. The most effective weight loss peptide available.
Evidence Score
High confidence
Category
Therapeutic area
Standard Dose
Once weekly injection
Half-life
Plasma elimination
Route
Subcutaneous
Safety Tier
Well characterized
Overview
Tirzepatide is "Ozempic 2.0." It hits TWO hunger hormones instead of one, so people lose even more weight. Up to 25% of body weight in trials. This is the most effective weight loss drug ever made.
Mechanism of Action
Dual GLP-1 and GIP receptor agonist that provides superior glycemic control and weight loss compared to GLP-1 agonists alone.
pH & Mixing
Peptides reconstituted at very different pH levels can destabilize when combined in the same syringe, which lowers how much of the peptide your body actually absorbs. If you're unsure whether two peptides are close enough in pH, reconstitute and inject them separately.
A dedicated compatibility check between two specific peptides is coming to the Compare tool. This section covers this peptide's pH only.
Benefits
- Best-in-class weight loss (20-25%)
- Works on two hormone pathways
- Excellent blood sugar control
- Reduces heart disease risk
- FDA approved
Side Effects
- Nausea
- Diarrhea
- Vomiting
- Reduced appetite
- Injection site reactions
Contraindications
- Pregnant or breastfeeding women
- Individuals under 18 years old
- Those with known allergies to peptide components
Structure & Sequence
Verified structure
Tirzepatide
Exact 2D structure can be rendered from a PubChem-backed canonical SMILES string.
- Amino Acid Sequence
- YXEGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPS-NH2 (39aa, Aib at positions 2,13; C20 diacid at Lys20)
- Molecular Weight
- 4,813.45 Da
- Chemical Formula
- C225H348N48O68
- CAS Number
- 1384722-03-0
- Reconstituted pH
- 6.5-7.5
- InChIKey
- BTSOGEDATSQOAF-MCNPHUAVSA-N
Stack & Route Context
Stacks with
No entries listed.
Administration
Subcutaneous
Research Status
FDA-approved for type 2 diabetes and weight management. Dual GLP-1/GIP agonist with superior efficacy to semaglutide in trials.
Approval Status
Approved
Sports Legal
Permitted
References
- 1View source
SURMOUNT-1: Tirzepatide for obesity
2022
- 2View source
Tirzepatide dual GIP/GLP-1 receptor agonist
2022
This profile summarizes research literature for education only. It is not medical advice, and it does not diagnose, treat, or recommend a dose. Consult a qualified professional before changing a protocol.